ACR staff have highlighted critical changes for the 2022 performance year outlined in the proposed rule released July 13 by the Centers for Medicare & Medicaid Services.
Search results for: melanoma
Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care
Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.
Case Report: Digital Ulcers & Weight Loss in a Pediatric Patient
Juvenile dermatomyositis (JDM) is a childhood form of inflammatory myopathy affecting children younger than 18 years. The diagnosis of JDM is based on characteristic clinical features of proximal muscle weakness, skin rash, elevated muscle enzymes, magnetic resonance imaging and muscle biopsy.1 Autoantibodies seen in patients with inflammatory myopathy are not only associated with particular phenotypes…
Myositis Management: Clinical Trials Provide New Insights into Treatment Options
Advancements in the treatment of myositis are on their way, according to Hector Chenoy, PhD, FRCP, who outlined the latest clinical trials during the 2021 ACR State-of-the-Art Clinical Symposium.
Case Report: Rapidly Progressive Interstitial Lung Disease in a 6-Year-Old
Clinically amyopathic dermatomyositis (CADM), a rare subset of dermatomyositis (DM), is an autoimmune disease characterized by cutaneous findings of typical DM without evidence of myositis. Childhood presentation of CADM is rare, and not many studies describe the epidemiology of juvenile CADM.1,2 Although lung disease is rare among patients with juvenile DM, a few reports have…
Reassuring Data on Immune Checkpoint Inhibitors in Autoimmune Disease
NEW YORK (Reuters Health)—Patients with preexisting autoimmune disease (AIDs) are not at increased risk for immune-related adverse events from immune checkpoint inhibitor (ICI) therapy, although these adverse events may be more likely in patients with inflammatory bowel disease (IBD), new research indicates. “Therefore, we encourage physicians not to withhold ICI in most common AIDs. However,…
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
Interfering with Interferon: Experts Discuss IFN Signaling & IFN Inhibition Treatment Possibilities
NIH investigators describe key features and genetic causes of Mendelian interferonopathies, & treatment approaches that may indicate the efficacy of IFN inhibition.
Long-Term Safety of Baricitinib for RA
Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.
Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »